QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-maintains-overweight-on-uniqure-lowers-price-target-to-60

Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $80 to $60.

 chardan-capital-maintains-buy-on-uniqure-maintains-53-price-target

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and maintains $53 price target.

 leerink-partners-maintains-outperform-on-uniqure-lowers-price-target-to-60

Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from ...

 correction-uniqure-q3-eps-138-misses-090-estimate-sales-3701m-miss-5243m-estimate

uniQure (NASDAQ:QURE) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.90) by ...

 biohaven-stock-hits-52-week-low-cuts-rd-spending-after-fda-rejection

Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Bl...

 fdas-rigid-approach-adds-uncertainty-to-uniqures-accelerated-pathway-for-huntingtons-gene-therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval ...

 goldman-sachs-maintains-neutral-on-uniqure-lowers-price-target-to-38

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and lowers the price target from $56 to...

 rbc-capital-maintains-outperform-on-uniqure-lowers-price-target-to-45

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the price target from $65 to $45.

 william-blair-downgrades-uniqure-to-market-perform

William Blair analyst Sami Corwin downgrades uniQure (NASDAQ:QURE) from Outperform to Market Perform.

 hc-wainwright--co-maintains-buy-on-uniqure-lowers-price-target-to-70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target f...

 chardan-capital-maintains-buy-on-uniqure-lowers-price-target-to-53

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $76 to $53.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION